15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)

Inclusion Criteria: * Women without childbearing potential * Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD) at screening * Estimated glomerular filtration rate of \< 60 mL/min/1.73 m2 (Modification of Diet in Renal Disease \[MDRD\] or the formula according to Matsuo, et al) * Not on dialysis and not expected to begin dialysis during the treatment period of the study (at least 16 weeks from randomization) * Not treated with any erythropoiesis-stimulating agent (ESA) within 8 weeks before randomization * Mean screening Hb concentration \</= 10.5 g/dL * Body weight of 45 kg to 125 kg, inclusive, at screening Exclusion Criteria: * Subjects with significant acute or chronic bleeding, such as overt gastrointestinal bleeding * Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission * Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated \> 3 years prior to randomization * Subjects treated with any ESA within the 8 weeks before randomization * Red blood cell (RBC) containing transfusion within the 8 weeks before randomization * History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism) within the last 6 months from initial screening visit * Severe rhythm or conduction disorders (e.g., HR \< 50 or \> 110 bpm, atrial flutter, prolonged QT \> 500 msec, third degree atrioventricular \[AV\] block) * New York Heart Association Class III or IV congestive heart failure * Severe hepatic insufficiency (defined as alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \> 3 x the upper limit of normal \[ULN\], total bilirubin \> 2 mg/dL, or Child-Pugh B and C) or active hepatitis, in the investigator's opinion